Today: 14 May 2026
Browse Category

Pharmaceuticals 23 January 2026 - 25 January 2026

AbbVie stock price: India patent setback on Venclexta puts ABBV in focus before Feb. 4 earnings

AbbVie stock price: India patent setback on Venclexta puts ABBV in focus before Feb. 4 earnings

AbbVie shares rose 0.5% to $219.26 Friday, shrugging off India’s rejection of its patent application for the cancer drug venetoclax. The Indian patent office cited lack of novelty and opposition from seven parties. AbbVie will report Q4 and full-year earnings on Feb. 4. Investors remain focused on patent risks and upcoming guidance as the company adjusts after Humira’s decline.
25 January 2026
···
AstraZeneca stock faces a new test: Iraq terrorism lawsuit revived with NYSE move days away

AstraZeneca stock faces a new test: Iraq terrorism lawsuit revived with NYSE move days away

A U.S. appeals court on Friday revived a lawsuit accusing AstraZeneca and other firms of funding terrorism in Iraq. The ruling was announced after U.S. markets closed; AstraZeneca shares had closed up 1.37% in New York and 0.15% in London. The company plans to switch its U.S. listing from Nasdaq to NYSE on Jan. 30. Investors await Monday’s market reaction.
24 January 2026
··
Novo Nordisk Class B stock heads into Monday with Wegovy pill scripts and Victoza lawsuit in focus

Novo Nordisk Class B stock heads into Monday with Wegovy pill scripts and Victoza lawsuit in focus

Novo Nordisk Class B shares closed up 1.17% at 401.35 crowns in Copenhagen, lifted by strong early U.S. demand for its new Wegovy pill. The company faces a new U.S. lawsuit alleging a “pay-for-delay” scheme for Victoza. Over 18,000 Wegovy pill prescriptions were reported in the U.S. since its Jan. 5 launch. Indian regulators approved local firms to make generic semaglutide ahead of the 2026 patent expiry.
24 January 2026
··
Eli Lilly stock slips as obesity-drug headlines pile up ahead of next week

Eli Lilly stock slips as obesity-drug headlines pile up ahead of next week

Eli Lilly shares fell 2.1% to $1,064.29 Friday after analysts reported Novo Nordisk’s new Wegovy pill logged 18,410 U.S. prescriptions in its first full week. Lilly’s Q4 results are due Feb. 4. India approved local firms to make generic semaglutide ahead of its 2026 patent expiry. New data showed many patients did not quickly regain weight after stopping GLP-1 drugs.
24 January 2026
···
Moderna stock pulls back after a sharp rally as investors weigh U.S. vaccine backlash risk

Moderna stock pulls back after a sharp rally as investors weigh U.S. vaccine backlash risk

Moderna shares fell 6.09% to $48.71 Friday after CEO Stéphane Bancel said the company will scale back new late-stage vaccine trials, citing U.S. resistance and policy delays. The drop followed a midweek rally on positive cancer vaccine data with Merck. Investors await Moderna’s Feb. 13 results for further updates. U.S. markets are closed until Monday.
24 January 2026
···
Sarepta stock eyes a Monday swing as Elevidys 3-year EMBARK data gets a date

Sarepta stock eyes a Monday swing as Elevidys 3-year EMBARK data gets a date

Sarepta shares rose about 5% in after-hours trading Friday after the company announced it will release three-year Phase 3 data for its Duchenne gene therapy, Elevidys, on Jan. 26. The update follows recent FDA restrictions and safety warnings after deaths in non-ambulatory patients. Investors are watching for data on durability and safety. Sarepta will hold a webcast Monday morning to present the results.
24 January 2026
··
GSK share price in focus after China clears Trelegy for asthma — what to watch next week

GSK share price in focus after China clears Trelegy for asthma — what to watch next week

GSK shares closed down 0.2% at 1,801 pence in London Friday after China approved Trelegy Ellipta for uncontrolled asthma in adults. The expanded label gives GSK access to an estimated 46 million adults with asthma in China. Investors await GSK’s Q4 and full-year results, set for Feb. 4. The FTSE 100 slipped 0.07% on the day.
24 January 2026
·····
Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings

Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings

Pfizer shares fell 1.9% to $25.62 Friday as the stock went ex-dividend, nearly matching the $0.43 payout. The drop outpaced the health-care sector, with Moderna tumbling over 7% and Merck down 1%. Policy changes under Health Secretary Robert F. Kennedy Jr. have unsettled vaccine makers. Pfizer reports quarterly results and hosts a webcast on Feb. 3.
23 January 2026
·····
Eli Lilly stock slips as Novo’s Wegovy pill racks up 18,000+ scripts; earnings next

Eli Lilly stock slips as Novo’s Wegovy pill racks up 18,000+ scripts; earnings next

Eli Lilly shares fell 1.1% to $1,075.78 after Novo Nordisk’s new Wegovy pill logged over 18,000 U.S. prescriptions in its first full week. Investors are watching ahead of Lilly’s Feb. 4 earnings and an expected FDA decision on its own oral obesity drug by April. Several Lilly directors recently received stock units through a deferral plan.
23 January 2026
····
Johnson & Johnson stock today: Why JNJ can’t break out as talc risk shadows upbeat 2026 outlook

Johnson & Johnson stock today: Why JNJ can’t break out as talc risk shadows upbeat 2026 outlook

Johnson & Johnson shares traded nearly flat at $218.59 by late Friday morning as Wall Street upgrades met renewed worries over federal talc lawsuits. A special master recommended allowing plaintiffs’ experts to testify that J&J talc products can cause ovarian cancer, affecting over 67,500 cases. The company reported Q4 sales up 9.1% to $24.6 billion and projected 2026 sales of up to $101 billion.
23 January 2026
··
India’s Q3 results rush: IndusInd Bank profit seen plunging as JSW Steel, BPCL, Cipla report today

India’s Q3 results rush: IndusInd Bank profit seen plunging as JSW Steel, BPCL, Cipla report today

Over 50 Indian companies, including IndusInd Bank, JSW Steel, BPCL, and Cipla, will report December-quarter earnings on Friday. Brokerages expect IndusInd Bank’s profit after tax to drop sharply, with forecasts ranging from 13 crore to 313 crore rupees. JSW Steel faces weaker prices, while BPCL may see higher EBITDA due to softer crude. Pharma and banking sectors remain under pressure.
23 January 2026
······
1 … 10 11 12 13 14 … 40

Stock Market Today

  • NVIDIA Stock Rises 2.29% with Strong Technical Indicators but Volume Divergence Signals Caution
    May 13, 2026, 10:42 PM EDT. NVIDIA's stock price increased 2.29% on May 13, 2026, continuing a six-day winning streak and rising 7.92% over two weeks. Notably, the stock broke a strong short-term trend line at $223.03, suggesting further gains toward the $264.30 resistance level. Moving averages signal a buy, with the short-term trend above the long-term. However, declining volume despite rising prices may indicate a potential reversal. Support levels are identified at $213.87, $195.72, and $184.89, with sell signals triggered if these break. Technical caution is advised due to a sell signal from the 3-month MACD indicator and volume-price divergence. Market watchers should monitor NVIDIA closely for short-term shifts amid medium risk trading conditions.

Latest articles

Enovix Stock Drops After Q1 Beat as Smartphone Battery Tests Stay Unfinished

Enovix Stock Drops After Q1 Beat as Smartphone Battery Tests Stay Unfinished

14 May 2026
Enovix shares dropped 12.9% to $6.35 after hours Wednesday despite beating first-quarter revenue and adjusted-loss estimates. The decline followed news that smartphone battery qualification remains unfinished, with the company passing 72 of 75 customer tests. Revenue rose 49% to $7.6 million. Enovix cited progress in defense, industrial, and smart-eyewear sales.
Lightwave Logic Stock Jumps as AI-Photonics Bet Heads for a 2027 Production Test

Lightwave Logic Stock Jumps as AI-Photonics Bet Heads for a 2027 Production Test

14 May 2026
Lightwave Logic reported Q1 revenue up 27% to $29,000 and a net loss widening to $6.3 million. Shares rose 14% after the company said it is negotiating a supply and licensing deal for high-volume production in 2027. Four Fortune 500 customers are now in Stage 3 prototyping. Cash and equivalents totaled about $100 million as of May 11.
USA Rare Earth Stock Watch: Q1 Revenue, $1.75 Billion Cash and the China Supply Crunch

USA Rare Earth Stock Watch: Q1 Revenue, $1.75 Billion Cash and the China Supply Crunch

14 May 2026
USA Rare Earth reported Q1 revenue of $5.7 million and a net loss of $67 million, ending March with $1.75 billion in cash after a $1.5 billion PIPE. The company expects to sign documents this month for $1.6 billion in U.S. Commerce Department funding. Texas awarded a $14.18 million grant for the Round Top project. USA Rare Earth agreed in April to acquire Brazil’s Serra Verde for $2.8 billion.
Go toTop